INTERNATIONAL STANDARD

ISO 10993-7

Second edition
2008-10-15

AMENDMENT 1
2019-12

Biological evaluation of medical devices —

Part 7: Ethylene oxide sterilization residuals

AMENDMENT 1: Applicability of allowable limits for neonates and infants

Reference number
ISO 10993-7:2008/Amd.1:2019(E)

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Fax: +41 22 749 09 47
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 194, *Biological and clinical evaluation of medical devices*.

A list of all parts in the ISO 10993 series can be found on the ISO website.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Biological evaluation of medical devices —

Part 7:
Ethylene oxide sterilization residuals

AMENDMENT 1: Applicability of allowable limits for neonates and infants

Normative references

Replace the reference to ISO 10993-1:— (including the footnote) with the following:

> ISO 10993-1:2018, *Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process*

4.2, second paragraph

Replace the reference "ISO 10993-1:—, 5.3:" with "ISO 10993-1:2018, 5.3:".

4.2, a) to c)

Replace the text with the following:

a) Limited exposure (A) – medical devices whose cumulative sum of single, multiple or repeated duration of contact is up to 24 h.

b) Prolonged exposure (B) – medical devices whose cumulative sum of single, multiple or repeated contact time is likely to exceed 24 h but not exceed 30 d.

c) Permanent exposure (C) – medical devices whose cumulative sum of single, multiple or repeated contact time exceeds 30 d.

4.3.1, second paragraph

Replace the paragraph with the following:

> The limits for permanent contact and prolonged exposure devices are expressed as maximum average daily doses. These limits carry additional constraints for the first 24 h of the exposure period and, in the case of the permanent contact devices, for the first 30 days, whichever extraction method is used. These constraints place limitations on the amount of EO and ECH that can be delivered to the patient during these early time periods.

4.3.1, third paragraph

Add a new paragraph:

If data are available, consideration should be given for proportioning the limits downward if multiple devices with the residue of concern are used at one time, e.g. multi-device systems, convenience kits, or proportioning the limits upward when device use is only for a part of the exposure period of concern. These concomitant exposure factors (CEF) and proportional exposure factors (PEF) are given in ISO 10993-17. A default value of 0,2 for CEF have been given for 5 medical devices used and contributing to the patient residues daily exposure.

4.3.2, first paragraph

Replace the paragraph with the following:

In the case of a device used in an adult of body mass m_b = 70 kg, and with CEF = 0,2 and PEF = 1,0 (default factors), the average daily dose of EO to patient shall not exceed 0,1 mg/d. In addition, the maximum EO dose shall not exceed:

4.3.2, last paragraph

Replace the paragraph with the following:

When the device is intended to be used in special populations, the appropriate patient body mass shall be used for the derivation of the allowable limits. For example, if the device is intended to be used in premature neonates, neonates or children, the allowable limits shall be derived using the TI value of 0,02 mg/kg/day for EO and 0,029 mg/kg/day for ECH as established in G.6.4 and H.4.1.3, respectively. The appropriate default body mass used for each category of special patient population shall be justified and documented.

4.3.3, first paragraph

Replace the paragraph with the following:

In the case of a device used in an adult of body mass m_b = 70 kg, and with CEF = 0,2 and PEF = 1,0 (default factors), the average daily dose of EO to patient shall not exceed 2,0 mg/d. In addition, the maximum EO dose shall not exceed:

4.3.3, last paragraph

Replace the paragraph with the following:

When the device is intended to be used in special populations, the appropriate patient body mass shall be used for the derivation of the allowable limits. For example, if the device is intended to be used in premature neonates, neonates or children, the allowable limits shall be derived using the TI value of 0,3 mg/kg/day for EO and 0,27 mg/kg/day for ECH as established in G.6.3 and H.4.1.2, respectively. The appropriate default body mass used for each category of special patient population shall be justified and documented.

4.3.4

Replace the text with the following:

In the case of a device used in an adult of body mass m_b = 70 kg, and with CEF = 0,2 and PEF = 1,0 (default factors), the average daily dose of EO to patient shall not exceed 4 mg. The average daily dose of ECH to patient shall not exceed 9 mg.

When the device is intended to be used in special populations, the appropriate patient body mass shall be used for the derivation of the allowable limits. For example, if the device is intended to be used in premature neonates, neonates or children, the allowable limits shall be derived using the TI value of 0,3 mg/kg/day for EO and 0,64 mg/kg/day for ECH as established in G.6.2 and H.4.1.1, respectively. The appropriate default body mass used for each category of special patient population shall be justified and documented.

B.2.1, second paragraph

Add the following sentence to the end of the paragraph:

Guidance on analytical method validation is available in numerous guidelines including ICH Q2 (R2) (see Bibliography).

B.2.1, third paragraph

Delete the second and third sentence of this paragraph.

C.1, second paragraph

Replace the text of the second sentence with the following:

Maximum allowable limits for ethylene chlorohydrin residues where ECH has been found to be present in medical devices sterilized with EO are also specified in the case of a device used in an adult of body mass m_b = 70 kg, and with CEF = 0,2 and PEF = 1,0 (default factors).

C.1, Table C.1

Replace the heading with the following:

Summary of allowable limits in adults for EO and ECH (limits per device). See also Figure C.1.

C.2.6

Replace the text of the first paragraph with the following:

For permanent exposure medical devices (those contacting the patient for longer than 30 d to a lifetime), exhaustive extraction is preferred. If another procedure is used this should be justified and documented.

C.2.7

Replace the second paragraph by the following:

a) If the measured EO and ECH are not more than 60 mg, go to C.2.7 b). Otherwise, use appropriate temperatures (either 37 °C or 25 °C) and times (based on anticipated use time) with water as the extracting medium to simulate product use (see C.3). If the measured EO and ECH dose, where ECH has been found, is not more than 60 mg, go to C.2.7 b). Otherwise, reduce EO and/or ECH.

b) If the measured EO and ECH are not more than 4 mg and 9 mg, respectively, go to C.2.9. Otherwise, use appropriate temperatures (either 37 °C or 25 °C) for 24 h with water as the extracting medium

to simulate product use (see C.3). If the measured EO and ECH doses from simulated use are not more than 4 mg or 9 mg respectively, go to C.2.9. Otherwise, reduce EO and/or ECH.

C.3.6, Figure C.3

Replace Figure C.3 with the following figure, which includes footnote f:



Bibliography

[1] ISO 11135:2007

Replace the above reference with the following one:

[1] ISO 11135:2014, *Sterilization of health-care products — Ethylene oxide — Requirements for the development, validation and routine control of a sterilization process for medical devices*

[2] AAMI EO VRSU 3/81

Replace the above reference with the following one:

[2] Association for the Advancement of Medical Instrumentation, *Good Hospital Practice: Ethylene Oxide Gas — Ventilation Recommendations and Safe Use*, Arlington, VA, 1987

[14] AAMI ST30 1989

Delete this reference and renumber the subsequent references.

[15] ASTM E691-05

Replace the above reference with the following one:

[14] ASTM E691-18, Standard practice for conducting an interlaboratory study to determine the precision of a test method

[17] ATSDR (1997)

Replace the above reference with the following one:

[16] ATSDR. Toxicological profile for ethylene glycol and propylene glycol. Atlanta, GA, 2010

Add the following references at the end of the Bibliography:

[207] Validation of analytical procedures: Text and methodology Q2 (R1), ICH Harmonised Tripartite Guideline, November 2005

[208] Harmonized Guidelines for Single Laboratory Validation Methods of Analysis (IUPAC Technical Report). Pure Appl. Chem., Vol. 74, No. 5, pp. 835.855, 2002

[209] AOAC Guidelines for Single Laboratory Validation of Chemical Methods for Dietary Supplements and Botanicals (December 12, 2002)

[210] Guidance for industry - Analytical Procedures and Methods Validation for Drugs and Biologics, US. Department of Health and Human Services, FDA, July 2015

[211] Harmonisation of strategies for the validation of quantitative analytical procedures A SFSTP proposal Part I. J. Pharm. Biomed. Anal. 2004, 36 pp. 579–586

[212] Eurachem, The Fitness for Purpose of Analytical Methods, A Laboratory Guide to Method Validation and Related Topics. Second Edition, 2014

ICS 11.100.20

Price based on 5 pages